• Proceedings of the PSK Conference
• /
• 2003.10a
• /
• pp.54-55
• /
• 2003

Radiation therapy has been used for the cancer treatment externally or internally. The external radiation therapy has been widely used, but for the lack of its selectivity it requires strong radiation dose causing the dermal irritation and radiation effect of the normal tissues or organs. So we investigate non-clinical and clinical studies of “Milican inj.”, in which chitosan is chelated with 166-Holmium, as an anticancer agent for internal radiation therapy. (omitted)

• Advances in nano research
• /
• v.10 no.4
• /
• pp.397-414
• /
• 2021

The steady growth in population has led to an enhanced water demand and immense pressure on water resources. Pharmaceutical residues (PRs) are unused or non-assimilated medicines found in water supplies that originate from the human and animal consumption of antibiotics, antipyretics, analgesics etc. These have been detected recently in sewage effluents, surface water, ground water and even in drinking water. Due to their toxicity and potential hazard to the environment, humans and aquatic life, PRs are now categorized as the emerging contaminants (ECs). India figures in the top five manufacturers of medicines in the world and every third pill consumed in the world is produced in India. Present day conventional wastewater treatment methods are ineffective and don't eliminate them completely. The use of nanotechnology via advanced oxidation processes (AOP) is one of the most effective methods for the removal of these PRs. Present study is aimed at reviewing the presence of various PRs in water supplies and also to describe the process of AOP to overcome their threat. This study is also very important in view of World Health Organization report confirming more than 30 million cases of COVID-19 worldwide. This will lead to an alleviated use of antibiotics, antipyretics etc. and their subsequent occurrence in water bodies. Need of the hour is to devise a proper treatment strategy and a decision thereof by the policymakers to overcome the possible threat to the environment and health of humans and aquatic life.

• Asian Pacific Journal of Cancer Prevention
• /
• v.15 no.16
• /
• pp.6829-6835
• /
• 2014

Chemotherapy is the primary therapy for malignant lymphoma (ML). However, the clinical outcome is still far from satisfactory. Consequently, an understanding of the mechanism of modulating cancer cell invasion, migration and metastasis is important for the development of more effective chemotherapeutic agents. FNC, 2'-deoxy-2'-${\beta}$-fluoro-4'-azidocytidine, a novel cytidine analogue, has demonstrated significantly inhibitory effects on proliferation of several non-Hodgkin lymphoma (NHL) cell lines. A previous study indicated that FNC effectively inhibited the growth of Raji and JeKo-1 cells in dose-time dependent effects with $IC_{50}$ values of $0.2{\mu}M$ and $0.097{\mu}M$, respectively. This study was focused on investigating the anti-invasive properties of FNC on NHL cells and its potential mechanisms of action. Cell adhesion and transwell chamber assays were utilized to investigate the anti-invasive effects of FNC on Raji and JeKo-1 cells. Real-time PCR and Western blotting were employed to qualify the expression of ${\beta}$-catenin, the glycogen synthase kinase-3 beta (GSK-$3{\beta}$), E-cadherin vascular endothelial growth factor (VEGF), matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). The results revealed that FNC remarkably inhibited the adhesion, migration and invasion of two human aggressive non-Hodgkin lymphoma cell lines in a dose dependent manner. Furthermore, ${\beta}$-catenin, MMP-2, MMP-9, VEGF mRNA and protein levels were decreased after FNC treatment, while GSK-$3{\beta}$ and E-cadherin increased. Our studies thus provide evidence and a rationale that FNC may offer an effective chemotherapeutic agent by regulating the invasion and metastasis of aggressive non-Hodgkin lymphoma via inhibition of the Wnt/${\beta}$-catenin signaling pathway.

• Macromolecular Research
• /
• v.15 no.2
• /
• pp.100-108
• /
• 2007

Gene therapy has become a promising strategy for the treatment of genetically based diseases, such as cancer, which are currently considered incurable. A major obstacle in the field of cancer gene therapy is the development of a safe and efficient delivery system for therapeutic gene transfer. Non-viral vectors have attracted great interest, as they are simple to prepare, stable, easy to modify and relatively safe compared to viral vectors. In this review, an insight into the strategies developed for polyethylenimine (PEI)-based non-viral vectors has been provide, including improvement of the polyplex properties by incorporating hydrophilic spacer, poly(ethylene glycol) (PEG). Moreover, this review will summarize the strategies for the tumor targeting. Specifically, a targeted polymeric gene delivery system, PEI-g-PEG-RGD, will be introduced as an efficient gene delivery vector for tumor therapy, including its functional analysis both in vitro and in vivo.

• YAKHAK HOEJI
• /
• v.35 no.2
• /
• pp.119-122
• /
• 1991

A convenient method for the synthesis of ibuproxam, which is a non steroidal antiinflammatory agent, is reported. Friedel-Crafts reaction of isobutylbenzene with ethyl $\alpha$-chloro-$\alpha$-(methylthio)acetate (3) gives ethyl $\alpha$-methylthio-(p-isobutylpheny) acetate (4). Ethyl 2-methylthio-2-(4-isobutylphenyl) propionate (5) is obtained from methylation of the compound (4) with NaH and Mel. lbuproxam (7) is easily synthesized by reductive desulfurization of the compound (5) with zinc dust-acetic acid or Raney nickel, followed by treatment of the resultant ethyl 2-(4-isobutyl-pheny) propionate (6) with H$_{2}$NOH-HCI.

• YAKHAK HOEJI
• /
• v.35 no.2
• /
• pp.131-134
• /
• 1991

A new method for the synthesis of butibufen, which is a non steroidal anti-iriflammatory agent, is described. Friedel-Crafts reaction of isobutylbenzene with ethyl $\alpha$-chloro-.alpha.-(methylthio) acetate (1) gives ethyl $\alpha$-methylthio-(p-isobutylphenyl)acetate (2). Ethyl 2-methylthio-2-(4-isobutylphenyl)butyrate (3) is obtained from treatment of the compound (2) with NaH and Etl. Butibufen (5) is synthesized by reductive desulfurization of the compound (3) with zinc dust-acetic acid or Raney nickel, followed by hydrolysis of the resultant ethyl 2-(4-isobutylphenyl)butyrate (4).

• Asian Pacific Journal of Cancer Prevention
• /
• v.15 no.14
• /
• pp.5691-5696
• /
• 2014

Background: Many clinical trials have been conducted to evaluate sorafenib for the treatment of advanced NSCLC, but the results for efficacy have been inconsistent. The aim of this study was to evaluate the efficacy and safety of sorafenib in patients with advanced NSCLC in more detail by meta-analysis. Methods: This meta-analysis of randomized controlled trials (RCTs) was performed after searching PubMed, EMBASE, ASCO Abstracts, ESMO Abstracts, and the proceedings of major conferences for relevant clinical trials. Two reviewers independently assessed the quality of the trials. Outcomes analysis were disease control rate (DCR), progression- free survival (PFS), overall survival (OS) with 95% confidence intervals (CI) and major toxicity. Subgroup analysis was conducted according to sorafenib monotherapy, in combination with chemotherapy or EGFR-TKI to investigate the preferred therapy strategy. Results: Results reported from 6 RCTs involving 2, 748 patients were included in the analysis. Compared to sorafenib-free group, SBT was not associated with higher DCR (RR 1.31 (0.96- 1.79), p=0.09), PFS (HR 0.82 (0.66-1.02), p=0.07) and OS (HR 1.01 (0.92-1.12), p=0.77). In terms of subgroup results, sorafenib monotherapy was associated with significant superior DCR and longer PFS, but failed to show advantage with regard to OS. Grade 3 or greater sorafenib-related adverse events included fatigue, hypertension, diarrhea, oral mucositis, rash and HFSR. Conclusions: SBT was revealed to yield no improvement in DCR, PFS and OS. However, sorafenib as monotherapy showed some activity in NSCLC. Further evaluation may be considered in subsets of patients who may benefit from this treatment. Sorafenib combined inhibition therapy should be limited unless the choice of platinum-doublet regimen, administration sequence or identification of predictive biomarkers are considered to receive better anti-tumor activity and prevention of resistance mechanisms.

• Proceedings of the Plant Resources Society of Korea Conference
• /
• 2023.04a
• /
• pp.53-53
• /
• 2023

Abeliophyllum distichum, one of the Korean endemic plant, is a significant pharmaceutical plant resource. A. distichum with phenylethanoid glycoside can use to regulate the development of cancer, DNA damage with radicals, and the generation of inflammatory mediators. In this study, we investigated whether the biomass, content of phenylethanoid glycoside, and growth rate of callus derived from A. distichum (cultivar Okhwang1, CAD) change in the absence or presence of plant hormones (2,4-Dichlorophenoxyacetic acid; 2, 4-D and 1-Naphthaleneacetic acid; NAA). The results showed that the best biomass, the growth rate of callus, and the contents of phenylethanoid glycoside were cultivated on Murashige and Skoog (MS) growth medium fortified with 1 ppm 2,4-D + 2 ppm NAA after 4 weeks. In a further study, CAD was cultivated on MS growth medium fortified with an elicitor (Methyl Jasmonate, MeJA). The results showed that CAD turned to brown color and fragile form with the elicitor. HPLC-PDA analysis revealed that the contents of phenylethanoid glycoside in the elicitor-treated group were higher than in the elicitor-non-treated group. These results are consistent with the findings of Arano-Varela H et al.,'s study which is that acteoside production can increase after the treatment of MeJA. Therefore, this study can be used to develop an effective and sustainable production of useful substances as an alternative to plant cultivation.

• Environmental Engineering Research
• /
• v.19 no.1
• /
• pp.9-14
• /
• 2014

Fenton reaction with zerovalent iron (ZVI) and $Fe^{2+}$ ions was studied to treat pharmaceutical wastewaters (PhWW) including antibiotics and non-biodegradable organics. Incremental biodegradability was assessed by monitoring biochemical oxygen demand (BOD) changes during Fenton reaction. Original undiluted wastewater samples were used as collected from the pharmaceutical factory. Experiments were carried out to obtain optimal conditions for Fenton reaction under different $H_2O_2$ and ion salts (ZVI and $Fe^{2+}$) concentrations. The optimal ratio and dosage of $H_2O_2$/ZVI were 5 and 25/5 g/L (mass basis), respectively. Also, the optimal ratio and dosage of $H_2O_2/Fe^{2+}$ ions were 5 and 35/7 g/L (mass basis), respectively. Under optimized conditions, the chemical oxygen demand (COD) removal efficiency by ZVI was 23% better than the treatment with $Fe^{2+}$ ion. The reaction time was 45 min for ZVI and shorter than 60 min for $Fe^{2+}$ ion. The COD and total organic carbon (TOC) were decreased, but BOD was increased under the optimal conditions of $H_2O_2$/ZVI = 25/5 g/L, because organic compounds were converted into biodegradable intermediates in the early steps of the reaction. The BOD/TOC ratio was increased, but reverse-wise, the COD/TOC was decreased because of generated intermediates. The biodegradability was increased about 9.8 times (BOD/TOC basis), after treatment with ZVI. The combination of chemical and biological processes seems an interesting combination for treating PhWW.

• Biomolecules & Therapeutics
• /
• v.22 no.3
• /
• pp.260-266
• /
• 2014

This study evaluated the pharmacokinetic profile and therapeutic efficacy of piroxicam (PX), a long acting non-steroidal anti-inflammatory drug for the treatment of arthritis, following intra-articular (IA) injection in comparison to the pharmacokinetic profile and therapeutic efficacy of PX after intramuscular (IM) injection. In the pharmacokinetic study in rats, systemic exposure and pharmacokinetic parameters of PX after a single IA dose were compared with systemic exposure and pharmacokinetic parameters of PX after administration of the same dose IM (0.6 mg/kg). The anti-inflammatory and analgesic effects of IA PX were evaluated simultaneously in a monoiodoacetate-induced osteoarthritis rat model. The plasma PX concentration rapidly rose following IA injection, and it was comparable to the plasma PX concentration following IM injection, suggesting the rapid efflux of the drug molecule from the joint cavity. However, in the efficacy study, the IA PX administration significantly reduced the knee swelling by reducing the level of prostaglandin $E_2$ in the joint, compared to that following administration of IA vehicle and after administration of the IM PX dose. In addition, we found that the anti-inflammatory and anti-nociceptive efficacies of IA PX were synergistically increased upon co-treatment with hyaluronic acid (HA), a potent agent for the treatment of osteoarthritis, at the weight ratio of 1:1 or 1:2, and these effects were more pronounced than those following administration of HA or PX alone. In conclusion, this study demonstrated the efficacy of the IA use of PX alone and/or in combination with HA in osteoarthritis.